- Home
- ECBK vs VERU Comparison
ECBK vs VERU Comparison
Compare ECBK & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECBK
- VERU
- Stock Information
- Founded
- ECBK 1919
- VERU 1971
- Country
- ECBK United States
- VERU United States
- Employees
- ECBK N/A
- VERU N/A
- Industry
- ECBK Banks
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- ECBK Finance
- VERU Health Care
- Exchange
- ECBK Nasdaq
- VERU Nasdaq
- Market Cap
- ECBK 151.0M
- VERU 85.5M
- IPO Year
- ECBK N/A
- VERU 1990
- Fundamental
- Price
- ECBK $15.88
- VERU $3.54
- Analyst Decision
- ECBK
- VERU Strong Buy
- Analyst Count
- ECBK 0
- VERU 3
- Target Price
- ECBK N/A
- VERU $33.33
- AVG Volume (30 Days)
- ECBK 7.7K
- VERU 131.5K
- Earning Date
- ECBK 10-23-2025
- VERU 08-12-2025
- Dividend Yield
- ECBK N/A
- VERU N/A
- EPS Growth
- ECBK 52.06
- VERU N/A
- EPS
- ECBK 0.64
- VERU N/A
- Revenue
- ECBK $27,795,000.00
- VERU $16,886,419.00
- Revenue This Year
- ECBK N/A
- VERU N/A
- Revenue Next Year
- ECBK N/A
- VERU N/A
- P/E Ratio
- ECBK $25.21
- VERU N/A
- Revenue Growth
- ECBK 12.29
- VERU 337.24
- 52 Week Low
- ECBK $12.56
- VERU $2.64
- 52 Week High
- ECBK $17.33
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- ECBK 36.99
- VERU 45.20
- Support Level
- ECBK $15.16
- VERU $3.40
- Resistance Level
- ECBK $17.12
- VERU $3.94
- Average True Range (ATR)
- ECBK 0.38
- VERU 0.22
- MACD
- ECBK -0.15
- VERU 0.10
- Stochastic Oscillator
- ECBK 33.18
- VERU 44.44
About ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.